Janus Henderson Group
PTGX icon

Janus Henderson Group’s Protagonist Therapeutics PTGX Stock Holding History

Janus Henderson Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$305M Buy
2,891,527
+241,546
+9% +$21.4M 0.15% 148
2025
Q4 		$231M Buy
2,649,981
+1,549,160
+141% +$127M 0.1% 176
2025
Q3 		$73.2M Buy
1,100,821
+653,993
+146% +$37.2M 0.03% 334
2025
Q2 		$24.7M Buy
446,828
+425,374
+1,983% +$20.4M 0.01% 529
2025
Q1 		$1.05M Hold
21,454
– – ﹤0.01% 1598
2024
Q4 		$828K Hold
21,454
– – ﹤0.01% 1783
2024
Q3 		$965K Hold
21,454
– – ﹤0.01% 1685
2024
Q2 		$743K Sell
21,454
-281
-1% -$8.23K ﹤0.01% 1783
2024
Q1 		$628K Buy
21,735
+1
+0% +$27 ﹤0.01% 1897
2023
Q4 		$499K Sell
21,734
-41
-0.2% -$717 ﹤0.01% 1986
2023
Q3 		$364K Buy
21,775
+20
+0.1% +$388 ﹤0.01% 2095
2023
Q2 		$601K Buy
21,755
+4,505
+26% +$113K ﹤0.01% 1875
2023
Q1 		$397K Buy
+17,250
New +$290K ﹤0.01% 2144
2022
Q1 		– Sell
-8,014
Closed -$274K – 2694
2021
Q4 		$274K Buy
+8,014
New +$253K ﹤0.01% 2240

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group's PTGX Position: Q1 2026 in Review

Janus Henderson Group increased its Protagonist Therapeutics (PTGX) stake by 9.1% in Q1 2026, buying an estimated $21.4M and bringing the position to 2,891,527 shares worth $305M. The position accounts for 0.15% of the portfolio, ranked #148.

Janus Henderson Group first reported a position in PTGX in Q4 2021 and has held it in 14 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Janus Henderson Group held 2,891,527 shares of Protagonist Therapeutics worth $305M as of Q1 2026.
  • Janus Henderson Group bought 241,546 Protagonist Therapeutics shares in Q1 2026, an estimated $21.4M.
  • Protagonist Therapeutics made up 0.15% of Janus Henderson Group's portfolio in Q1 2026, its #148 holding.
  • Janus Henderson Group first reported a position in Protagonist Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.